The power of collaboration,
innovation, and
shared expertise


Stronger together

At SCDM, we believe in the power of collaboration, innovation, and shared expertise to shape the future of our industry. To facilitate this process, we have established a collection of specialized bodies dedicated to advancing the interests and fostering exchanges within specific industry cohorts. Admission to the SCDM bodies is strictly upon invitation. To register your interest, send us an email outlining your profile and the name of the body which you wish to join.


Fostering dialogue and interaction between regulators and the CDM profession

Recently launched, the SCDM Regulatory Council is a distinguished group of regulators from the FDA, participating under the principles of an official Public-Private Partnership, formed to increase dialogue and interaction between regulators and the CDM profession. These individuals bring a wealth of knowledge and insights amassed through years of experience, offering invaluable guidance and shaping our initiatives with their deep understanding of clinical trial data trends, challenges, and emerging opportunities. Their strategic counsel empowers the SCDM community to navigate complexities and stay at the forefront of what is possible. Watch this space for announcements about other key regulatory agencies joining the SCDM Regulatory Council in the future.


A platform for senior-level peer-to-peer exchanges

To discuss and tackle multifaceted challenges and foster senior-level peer-to-peer exchanges,in 2021 we have established the Biopharma Council. Composed of the most senior clinical data leaders within pharmaceutical companies, members of the Biopharma Council engage in regular, dynamic meetings where they share and explore what’s possible. The Biopharma Council is an informal group for off-the-record exchanges; consequently, meetings are held behind closed-doors and attendance is restricted. Participants join on an individual basis and work in the following companies Abbvie, Astellas, AstraZeneca, Bayer, BMS, Boston Scientific, Daiichi-Sankyo, Eli Lilly, EMD Serono, Exelis, Gilead, GSK, Johnson&Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Roche, and Sanofi.


Launching in 2024

In line with popular demand, we’re excited to announce that we will be launching the following SCDM bodies in the Autumn of 2024. Stay tuned for updates and opportunities to get involved!

  • Biotech Leadership Forum
  • CRO Leadership Forum
  • Tech Leadership Forum

Be the first to know

Sign up to get our latest news and industry updates.

By clicking the button you confirm that you agree with our terms and conditions.